Article
Oncology
Wenzhe Fan, Bowen Zhu, Xinlin Zheng, Shufan Yue, Mingjian Lu, Huishuang Fan, Liangliang Qiao, Fuliang Li, Guosheng Yuan, Yanqin Wu, Xinhua Zou, Hongyu Wang, Miao Xue, Jiaping Li
Summary: This study investigated the effectiveness and safety of combining sorafenib and drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of early intrahepatic stage-progressed advanced hepatocellular carcinoma (ISPA-HCC). The results showed that the combination therapy significantly improved tumor response rates, overall survival, and time to progression compared to sorafenib monotherapy. However, the DTS group had a higher incidence of adverse events during treatment.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Liang Cai, Honglu Li, Jiang Guo, Wenpeng Zhao, Youjia Duan, Xiaopu Hou, Long Cheng, Hongliu Du, Xihong Shao, Zhenying Diao, Changqing Li
Summary: DEB-TACE shows potential as an effective downstaging therapy for subsequent radical treatments, with a successful downstaging rate of 59.4% and a complete response rate of 81.3% after radical treatment. Successful downstaging is associated with longer progression-free survival (PFS) and overall survival (OS) in patients with unresectable HCC.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
(2021)
Article
Oncology
Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Yi-Hsiang Huang, Jia- Liao, Chien-Wei Su, Ming-Chih Hou, Teh-Ia Huo
Summary: Tumor burden score (TBS), estimated by the diameter and number of tumor nodules, is a feasible prognostic marker for HCC patients within the Milan criteria. Among patients with low TBS, radiofrequency ablation (RFA) should be considered the priority treatment modality.
Article
Oncology
Hao Li, Chao Liang, Donglin Kuang, Guohao Huang, Mengfan Zhang, Pengfei Chen, Qingzhu Zheng, Wenze Xu, Jianzhuang Ren, Xinwei Han, Xuhua Duan
Summary: This study evaluated the impact of drug-eluting bead transarterial chemoembolization (DEB-TACE) and conventional transarterial chemoembolization (cTACE) on hepatic fibrosis in hepatocellular carcinoma (HCC) patients. The results showed that DEB-TACE attenuates the progression of hepatic fibrosis and has comparable tolerance to cTACE in treating intermediate- or advanced-stage HCC.
CANCER BIOLOGY & THERAPY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Elisabeth Dhondt, Bieke Lambert, Laurens Hermie, Lynn Huyck, Peter Vanlangenhove, Anja Geerts, Xavier Verhelst, Maridi Aerts, Aude Vanlander, Frederik Berrevoet, Roberto Ivan Troisi, Hans Van Vlierberghe, Luc Defreyne
Summary: This study compared the efficacy and safety of Y-90 glass TARE and DEB-TACE for unresectable HCC. The results showed that TARE conferred superior tumor control and overall survival compared to DEB-TACE. Both treatments had similar safety profiles.
Article
Radiology, Nuclear Medicine & Medical Imaging
Lei Zhang, Jun-Hui Sun, Jian-Song Ji, Bin-Yan Zhong, Guan-Hui Zhou, Jing-Jing Song, Zhong-Heng Hou, Peng Huang, Shen Zhang, Zhi Li, Xiao-Li Zhu, Cai-Fang Ni
Summary: In the treatment of unresectable HCC patients, DEB-TACE was associated with higher rates of hepatobiliary injury and severe abdominal pain compared to cTACE, while local tumor disease control rates did not differ significantly between the two approaches.
AMERICAN JOURNAL OF ROENTGENOLOGY
(2021)
Article
Oncology
Chongkai Fang, Rui Luo, Ying Zhang, Jinan Wang, Kunliang Feng, Silin Liu, Chuyao Chen, Ruiwei Yao, Hanqian Shi, Chong Zhong
Summary: This study evaluated the efficacy and safety of preoperative neoadjuvant transcatheter arterial chemoembolization (TACE) for BCLC stage A/B hepatocellular carcinoma (HCC) patients beyond the Milan criteria. The results showed that neoadjuvant TACE significantly improved overall survival and progression-free survival compared to hepatectomy alone, without increasing severe adverse events.
FRONTIERS IN ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
William T. N. Culp, Eric G. Johnson, Michelle A. Giuffrida, Robert B. Rebhun, James K. Cawthra, Heidi A. Schwanz, Jenna H. Burton, Michael S. Kent
Summary: This study describes the use of a novel drug-eluting microsphere in transarterial chemoembolization for dogs with non-resectable hepatic neoplasia. The results show significant reduction in tumor volume and improvement in clinical signs.
Article
Oncology
Tan-Yang Zhou, Sheng-Qun Chen, Hong-Liang Wang, Sheng-Ming Weng, Guan-Hui Zhou, Yue-Lin Zhang, Chun-Hui Nie, Tong-Yin Zhu, Bao-Quan Wang, Zi-Niu Yu, Li Jing, Feng Chen, Jun-Hui Sun
Summary: This study evaluated the safety and efficacy of DEB-TACE with CSM in HCC patients with PVTT and found that higher Child-Pugh classification and tumor burden were significant prognostic factors for poor OS.
Article
Pharmacology & Pharmacy
Guangsheng Zhao, Song Liu, Songbai Chen, Zhizhong Ren, Chuang Li, Jie Bian, Jianlin Wu, Jun Zhou, Yuewei Zhang
Summary: In short-term efficacy, CalliSpheres group showed significantly higher objective response rate and disease control rate compared to the HepaSpheres group; however, there were no significant differences between the two groups in terms of long-term efficacy and safety.
Review
Gastroenterology & Hepatology
Leana Frankul, Catherine Frenette
Summary: Downstaging treatment is crucial for patients with unresectable hepatocellular carcinoma who are not eligible for liver transplantation, but severe organ shortage limits its broader application. Debate over the optimal treatment protocol and assessment method for downstaging treatment is pushing the boundaries of liver transplantation candidate selection.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2021)
Article
Medicine, General & Internal
Somin Lee, Yong Yeon Jeong, Byung Chan Lee, Sang Soo Shin, Suk Hee Heo, Hyoung Ook Kim, Chan Park, Won Gi Jeong
Summary: This study compared the long-term therapeutic outcomes of drug-eluting bead transarterial chemoembolization (DEB-TACE) with radiofrequency ablation (RFA) for the initial treatment of a single small hepatocellular carcinoma (HCC). The results showed that RFA had superior local tumor progression and progression-free survival rates compared to DEB-TACE, but there was no significant difference in overall survival rates. Therefore, DEB-TACE may be considered as an efficient substitute for RFA in some patients with a single small HCC who are ineligible for RFA.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2023)
Article
Oncology
Jianping Zhao, Jingjing Wang, Yuanxiang Lu, Yang Wu, Dong Kuang, Ying Wang, Hongchang Luo, Anhui Xu, Wanguang Zhang
Summary: The study suggests that neoadjuvant drug-eluting bead transarterial chemoembolization (DTACE) and tislelizumab therapy are safe and beneficial for patients with resectable or borderline resectable hepatocellular carcinoma (HCC), improving pathological results and prognosis.
Article
Oncology
Guangshao Cao, Yuyan Liu, Lupeng Li, Xiaoyang Zhao, Ruiqing Liu, Jian Liu, Jianwen Liu, Huicun Cao
Summary: This study compared the occurrence of adverse events (AEs) among radiofrequency ablation (RFA), conventional transarterial chemoembolization (cTACE), and drug-eluting bead TACE (DEB-TACE) in treating HCC patients. It found that cTACE resulted in the highest incidence of AEs, with male gender, bronchial asthma, and disease duration being independent predictive factors for total AEs risk.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Donglin Kuang, Nan Zhang, Mengfan Zhang, Hao Li, Xinwei Han, Jianzhuang Ren, Xuhua Duan
Summary: The purpose of this study was to investigate the morphological characteristics and clinical significance of peritumor margin enhancement on magnetic resonance (MR) images in hepatocellular carcinoma (HCC) patients after drug-eluting bead transcatheter arterial chemoembolization (DEB-TACE). The results showed that HCC patients with a sharp-type margin enhancement on MR images had lower levels of alpha-fetoprotein (AFP) and longer progression-free survival, indicating a benign prognosis. On the other hand, patients with a rough-type margin enhancement mostly demonstrated malignant growth.
FRONTIERS IN ONCOLOGY
(2023)